Insmed Announces Addition to the Russell 3000(R) Index
30 Juin 2009 - 2:00PM
PR Newswire (US)
RICHMOND, Va., June 30 /PRNewswire-FirstCall/ -- Insmed Inc.
(NASDAQ: INSM), a biopharmaceutical company, today announced that
it has been added to the Russell 3000 Index following Russell
Investments' reconstitution of its comprehensive set of U.S. and
global equity indexes on June 26, 2009. Insmed was also added to
the Russell Microcap(R) Index. Annual reconstitution of Russell's
U.S. indexes captures the 4,000 largest U.S. stocks as of the end
of May, ranking them by total market capitalization. Membership in
the Russell 3000, which remains in place for one year, means
automatic inclusion in the small-cap Russell 2000 Index, as well as
the appropriate growth and value style indexes. Russell determines
membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes. The Russell
3000 also serves as the U.S. component to the Russell Global Index,
which Russell launched in 2007. Russell indexes are widely used by
investment managers and institutional investors for index funds and
as benchmarks for both passive and active investment strategies. An
industry-leading $4 trillion in assets currently are benchmarked to
them. These investment tools originated from Russell's
multi-manager investment business in the early 1980s when the
company saw the need for a more objective, market-driven set of
benchmarks in order to evaluate outside investment managers. About
Russell Russell Investments provides strategic advice, world-class
implementation, state-of-the-art performance benchmarks and a range
of institutional-quality investment products. Russell has $136
billion in assets under management as of March 31, 2009, and serves
individual, institutional and advisor clients in more than 40
countries. Founded in 1936, Russell is a subsidiary of The
Northwestern Mutual Life Insurance Company. About Insmed Insmed
Inc. is a biopharmaceutical company with unique protein development
experience and a proprietary protein platform aimed at niche
markets with unmet medical needs. For more information, please
visit http://www.insmed.com/. Investor Relations Contact: Brian
Ritchie - FD 212-850-5683 Media Relations Contact: Irma Gomez-Dib -
FD 212-850-5761 DATASOURCE: Insmed Incorporated CONTACT: Investor
Relations, Brian Ritchie of FD, +1-212-850-5683, ; or Media
Relations, Irma Gomez-Dib of FD, +1-212-850-5761, Web Site:
http://www.insmed.com/
Copyright